Drug · DIN 02549891

CAPVAXIVE

SINGLE-DOSE PREFILLED SYRINGE

Yes: authorized and sold in Canada

Authorized, and the company reports that it sells it in Canada.

Status Marketed since August 29, 2024; first marketed August 29, 2024.

Drug Identification Number (DIN): 02549891
Company (DIN owner): Merck Canada IncKirkland, Quebec, Canada
Schedule: Schedule D
Dosage form: Solution
Route: Intramuscular
Therapeutic class (ATC): Pneumococcus, purified polysacc.antigen conjugated J07AL02
Class: Human
Record last updated: October 2, 2026

Active ingredients

As listed in the Drug Product Database.

Ingredient	Strength	Per
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 3	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 6A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 7F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 8	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 9N	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 10A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 11A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 12F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 15A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE DEOAC15B	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 16F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 17F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 19A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 20A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 22F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23A	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 23B	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 24F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 31	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 33F	4 MCG	0.5 ML
PNEUMOCOCCAL POLYSACCHARIDE SEROTYPE 35B	4 MCG	0.5 ML
CORYNEBACTERIUM DIPHTHERIAE CRM-197 PROTEIN	65 MCG	0.5 ML

Health Canada approvals that name this DIN.